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Background. One-stage direct-to-implant immediate breast reconstruction (IBR) is performed simultaneously with breast cancer
resection. We explored indications, techniques, and outcomes of IBR to determine its feasibility, safety, and effectiveness.
Material and Methods. We reviewed the available literature on one-stage direct-to-implant IBR, with or without acellular
dermal matrix (ADM), synthetic mesh, or autologous fat grafting. We analyzed the indications, preoperative work-up, surgical
technique, postoperative care, outcomes, and complications. Results. IBR is indicated for small-to-medium nonptotic breasts and
contraindicated in patients who require or have undergone radiotherapy, due to unacceptably high complications rates. Only
patients with thick, well-vascularized mastectomy flaps are IBR candidates. Expandable implants should be used for ptotic breasts,
while anatomical shaped implants should be used to reconstruct small-to-medium nonptotic breasts. ADMs can be used to cover
the implant during IBR and avoidmuscle elevation, therebyminimizing postoperative pain. Flap necrosis, reoperation, and implant
loss are more common with IBR than conventional two-staged reconstruction, but IBR has advantages such as lack of secondary
surgery, faster recovery, and better quality of life. Conclusions. IBR has good outcomes and patient-satisfaction rates. With ADM
use, a shift from conventional reconstruction to IBR has occurred. Drawbacks of IBR can be overcome by careful patient selection.
1. Background
Since skin- and nipple-sparing mastectomies have proven to
be oncologically safe, an increasing number of patients with
invasive breast cancer undergo breast reconstruction [1, 2].
Indeed, forwomenwhohave undergone amastectomy, breast
reconstruction provides psychosocial as well as aesthetic
benefits [3–5]. Breast reconstruction can be either allogeneic
(implant-based), autologous (locoregional flap, free flap), or
a combination of both. Reconstruction can be performed
simultaneously with mastectomy as a one- or two-stage
procedure, or it can be delayed and performed as a two-stage
procedure.
Implant-based reconstructions account for almost 65%
of all breast reconstructions in the USA [6, 7]. This type
of reconstruction is considered safe, cost effective, and
reliable; furthermore, it can be performed in women with
a wide variety of comorbid conditions [8, 9]. One-stage
immediate breast reconstruction (IBR) is a method to
reconstruct a definitive breast mound at the time of onco-
logic resection without the need for tissue expansion or
tissue expander/implant exchange. However, the likelihood
of requiring secondary procedure (e.g., scar revision, autol-
ogous fat grafting, nipple-areola complex (NAC) reconstruc-
tion, and matching surgery to the contralateral breast) is not
lower after one-stage IBR than after two-stage implant-based
IBR [10]. Given the fewer hospital accesses required, IBRmay
be convenient for both patients and the healthcare system
[10], and this partially explains the increasing number of
IBRs performed [11, 12].The recent introduction of acellular
dermal matrices (ADMs) and synthetic meshes has also
widened the indications for IBR [13–15].
Advocates of IBR highlight its advantages, which include
elimination of the expander-to-implant exchange, fast recov-
ery, better lower pole definition, and lower costs [16–18].
However, several studies have reported higher rates of com-
plications and implant loss with direct-to-implant IBR [19–
22].
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Given the conflicting reports, we aimed to identify
from the current literature the indications, techniques, and
outcomes of IBR in order to help surgeons in choosing
and performing the most suitable breast reconstruction for
each patient. We reviewed the available literature on one-
stage direct-to-implant IBR, with or without acellular dermal
matrix (ADM), synthetic mesh, or autologous fat grafting.
We analyzed the indications, preoperative work-up, surgical
technique, postoperative care, outcomes, and complications,
including the need for secondary procedures, of one-stage
direct-to-implant IBR.
2. General Considerations
Breast cancer is the most common malignancy in women
[23]. In 2011, it was estimated that nearly 230,000 women
were diagnosed with invasive breast cancer in the USA
alone [24]; 79% of the 96,277 patients who underwent
breast reconstructions underwent alloplastic-based breast
reconstruction [25]. Following advances in screening tests
and molecular genetics, many young women (aged <45
years) with inherited predisposition genes for breast cancer
are choosing to undergo bilateral prophylactic mastectomy
[26]. Even women with early-stage breast cancer suitable for
breast-conserving surgery may choose to undergo therapeu-
tic mastectomy and contralateral prophylactic mastectomy
[27].These youngwomenmay obtainmore pleasing cosmetic
outcomes bymeans of autologous reconstruction butmay not
agree to undergo major surgery, with more scar formation at
the donor site. Alloplastic breast reconstruction can ensure
satisfactory cosmetic outcomes in such patients with far
less-invasive surgery. Furthermore, more than 50% of breast
cancer cases occur in elderly women who may opt for a less-
invasive, one-stage procedure associatedwith early discharge,
rapid recovery, and a prompt return to everyday life [28].
3. Acellular Dermal Matrix and
Synthetic Mesh
Dieterich et al. [14] and Salzberg [29] first reported the use
of acellular dermal matrices (ADMs) for breast reconstruc-
tion. This strategy gradually spread among reconstructive
surgeons, even though early studies reported higher com-
plication rates with ADMs than with conventional breast
reconstruction [30, 31]. However, recent works have high-
lighted a reduction in complication rates, as a result of the
increased familiarity of plastic surgeonswith the use ofADMs
[32–34]. Currently, members of the American Society of
Plastic Surgeons use ADMs in more than 50% of their breast
reconstructions [35].
ADMs are made of extracellular matrix structures and
basement membrane complexes of either of fetal bovine,
porcine, or human cadaver origin [36]. ADMs lack immuno-
genic epitopes and are therefore revascularized, recellular-
ized, and integrated into host tissue with no evidence of
encapsulation, resorption, or contracture [37–41]. In breast
reconstructions with submuscular implants, ADMs can be
used as pectoral expanders to cover the inferolateral pole
of the implant and prevent the need for elevation of the
surrounding muscle, thus reducing postoperative pain [18,
42–44]. ADMs can also be used as an internal bra to
completely cover the implant during subcutaneous breast
reconstruction, anchoring the implant to the chest wall and
providing an additional layer of tissue supports, thereby
relieving the pressure on the mastectomy flaps [45–47].
Synthetic meshes were recently introduced as an alterna-
tive to ADMs in alloplastic breast reconstruction and have
shown promising results [15, 47–50]. Synthetic meshes are
safe and have aesthetic benefits similar to those obtained with
ADMs (improved inframammary fold definition, enhanced
lower pole shape and projection) without the drawbacks of
high cost and local policy restrictions.
Some authors have proposed that ADMs be substituted
with autologous dermal grafts harvested at the time of
mastectomy as a horizontally oriented ellipse in the lower
abdomen if a preexisting scar is present or from the contralat-
eral breast if a reductive mastoplasty is planned [51–53]. In a
prospective study, Lynch et al. [51] compared the outcomes of
dermal autograft- and ADM-assisted breast reconstructions.
They found that the major and minor complication rates as
well as total costs were higher in the ADM group, while
cosmetic outcomes did not significantly differ between the
ADM and autograft groups. Moreover, histological analysis
showed higher integration of the autograft into the sur-
rounding tissue, with extensive revascularization and vessel
ingrowth.
4. Immediate Breast Reconstruction
4.1. Indications. Direct-to-implant IBR aims to create a nat-
urally appearing breast mound in a single-stage surgery
without harnessing the mastectomy flap blood supply. Pre-
operative and intraoperative evaluations commonly guide
surgeons’ decision to perform IBR. Young, thin, and athletic
women with small-to-medium, nonptotic breasts are best
suited for IBR as well as SSM [54]. However, skin-reducing
mastectomy has broadened the indications of IBR to patients
with a very large breast skin envelope [55]. Nevertheless,
patients undergoing unilateral reconstruction must be aware
that they may eventually need to undergo contralateral
matching surgery [56].
ADM-assisted IBR enables the reconstruction of breasts
with varying degrees of ptosis [57]. In patients with a dis-
crepancy between muscular coverage and native breast skin-
flap coverage, ADMs can be used to lengthen the muscular
tissue plane to match the overlying skin envelope. Thus, the
reconstructed breast may be leftwith a natural pseudo-ptosis,
a well-defined inframammary fold, and enhanced inferior
pole projection, which better match the contralateral native
breast [58]. The estimated mastectomy weight should not
exceed 600 g [58]. Characteristics of the breast soft tissue, skin
elasticity of the trunk and overall body habitus are commonly
evaluated preoperative parameters [10].
As with expander-based breast reconstruction, direct-
to-implant IBR is reported to have higher complication
rates in patients who are scheduled to undergo adjuvant
radiotherapy orwho have a history of local irradiation; hence,
the indication of IBR in such patients remains controversial
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[59]. Unacceptably high complication rates (i.e., capsular
contracture and infection) have been reported with implant-
based reconstruction followed by radiation therapy [17, 18,
60], and delayed autologous tissue reconstruction after mas-
tectomy radiation therapy is generally regarded as the best
approach [61]. Nevertheless, increased surgical expertise and
improved target breast irradiation can pave the way to a safer
implant-based breast reconstruction even when adjuvant
radiotherapy is required [62–66]. Conflicting reports are
available regarding the use of ADMswhen adjuvant radiation
therapy is required [67–71].
Well-vascularized mastectomy skin flaps with an at least
1 cm thick subcutaneous layer are unanimously considered
to be essential to achieve successful outcomes [10, 72]. The
intraoperative judgment of the surgeon is recognized as the
singlemost important factor influencing the success of direct-
to-implant IBR [17, 34, 73, 74]. Indeed, only patients with
good-quality mastectomy flaps (thick and well-vascularized)
should be candidates for IBR to minimize the chances of
mastectomy flap necrosis [58]. The advent of intraoperative
objective assessment tools such as real-time perfusion map-
ping assisted by SPY! (Novadaq Technologies Inc., Bonita
Springs, FL, USA) has helped surgeons in this key decision-
making stage [75].
4.2. Preoperative Planning. The oncologic surgeon and the
plastic surgeon should perform the preoperative evalua-
tion together. Breast cancer localization, dimensions, and
nipple-areola involvement must be cautiously evaluated to
decide between skin-sparing mastectomy and nipple-sparing
mastectomy. Preoperative markings should favorably locate
the mastectomy scar, while preserving the required skin
envelope. The borders of the breast must be marked with
the patient standing upright, paying particular care in the
marking of the inframammary fold. The upper-pole border
should match the level of the contralateral breast, which
can be delineated by gently compressing the contralateral
breast against the chest wall. Nipple-to-sternal notch dis-
tance, areola-to-inframammary fold distance, and breast
width are measured at this stage. Skin quality, elasticity, and
thickness must also be carefully assessed. When contralateral
matching surgery is planned, preoperative markings are
also drawn on the contralateral breast, depending on the
procedure required. At this stage, surgeons should also bear
in mind the type and dimensions of the implant required
[13, 76].
When performing unilateral reconstruction in elderly
women with ptotic breasts, permanent expandable implants
provide good long-term cosmetic and oncologic outcomes
[10, 77]. Becker 25 and 50 (round) and Becker 35 (shaped)
implants (Mentor, Johnson & JohnsonMedical Ltd.,Woking-
ham, Berkshire, UK) as well as anatomical Style 150 implants
(Allergan Inc., Irvine, CA, USA) are commonly used per-
manent expandable biodimensional implants.These implants
differ not only in terms of the silicone elastomer used but
also in terms of their capacity; the Becker series implants
can be overinflated for at least 1 month and subsequently
deflated. This strategy allows matching to the contralateral
perimenopausal breast by creating a pseudo-ptotic effect,
lowering the position of the NAC, and lessening the final
projection [10, 77, 78].
Anatomic, shaped, silicone-filled implants are best suited
for recreating small-to-mild nonptotic breasts or when ADM
slings are required [13]. Indeed, silicone-filled implants tend
to lie flat against the chest wall; hence, anatomic shapes
provide appropriate volume restoration without excessive
superior-pole fullness. Even round implants can achieve good
results; however, there is a major risk of developing unpleas-
ing superior border step-off. Finally, the base diameter of
the implant should match that of the contralateral breast, for
both round and anatomically shaped implants [13]. Given the
complexity of this decision-making stage, surgical planning
and virtual simulator systems have been devised to train
surgeons outside of the “apprenticeship model” [79–81].
4.3. Surgical Technique. The mastectomy can be a simple
skin-sparing or skin-reducing NAC-sparing mastectomy [82,
83]. The mastectomy should be conducted in the space
between the subcutaneous adipose tissue and the glandular
parenchyma so as not to damage the subdermal plexus of the
mastectomy flaps and jeopardize their blood supply [47].The
inframammary fold is a crucial landmark of the breast and
must be conserved during mastectomy [84, 85]. If damaged,
it has to be restored using 4-5 braided silk or Vicryl! sutures
[56].
Once the mastectomy is completed, the surgeon should
assess skin-flap viability by evaluating skin-flap color, capil-
lary refill, temperature, turgor, and dermal bleeding [86]. Flu-
orescein angiography and laser-assisted indocyanine green
angiography can also be used to objectively assess the vitality
of themastectomyflaps [87, 88]. If theflaps are deemed viable,
direct-to-implant IBR can be performed.
At this stage, the reconstructive surgeon has various
options. An implant pocket can be created in either the
submuscular (partial or complete) or subcutaneous plane,
and ADMs, synthetic meshes, or dermal autografts can be
employed. Advocates of muscular coverage of implants aim
to maximize vascularity and prevent contact between the
implant and the overlyingmastectomy incision [56, 85].With
the patient in a supine position and the ipsilateral upper arm
adducted at 60∘, the pectoralismajormuscle is dissected from
its thoracic and sternal attachments, till the second rib [85].
A subpectoral pocket is superiorly dissected in a relatively
avascular plane, following the preoperativemarkings. Raising
either the serratus anterior muscle completely or its lower
slips only (to reduce postoperative pain) can achieve com-
plete muscular coverage of the implants [89].
A partial submuscular pocket can also be created by
elevating the serratus anterior muscle in a plane within
the muscle along with its overlying fascia, leaving the rib
cage covered by a portion of the muscle [82]. Inferiorly,
elevating the fascia of the anterior rectus muscle completes
the pocket. When a skin-reducing mastectomy is performed,
the dermal-adipose inferior flap is used for coverage of
the lower pole [90]. The submuscular pocket can also be
completed inferiorly with a rectangular 6 cm × 16 cm piece
of ADM, synthetic mesh, or dermal autograft. The chosen
graft is sutured to the inferior and lateral chest walls and
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Figure 1: Preoperative view (a) and postoperative result (b) after right breast skin-sparing mastectomy with radial lateral incision and one-
stage implant-based reconstruction after. Nipple-areola complex was reconstructed with local flap and tattooing. Matching surgery of the left
breast was not required.
to the inferior portion of the pectoralis muscle, acting as a
hammock for the lower pole of the chosen implant. ADMs,
synthetic meshes or dermal autografts should be accurately
tailored so as to prevent seromas, which may result from
discrepancies between muscular coverage and the native
breast skin envelope, contour irregularities, or dead space
[57].The adequacy of the position of the inframammary fold
and shape of the breast mound are assessed intraoperatively
by placing the patient in a sitting position. The definitive
implant can also be positioned in the subcutaneous pocket
resulting from the mastectomy.
The implant is completely wrapped by an ADM or
synthetic mesh so as to suture together the membrane. The
ADM-wrapped implant can be positioned into the subcuta-
neous pocket and secured in place to the underlying muscles
by means of apical, medial, and lateral absorbable stitches
[58].
Once the pocket has been created, it must be thoroughly
irrigated, and accurate hemostasis must be performed. Vari-
ous irrigant solutions have been proposed to prevent subclin-
ical pocket infection, which is regarded as a possible etiology
of capsular contracture [56]. The triple antibiotic of Adams
(comprising 80mg gentamicin, 1 g cefazolin, and 50,000U
bacitracin [or equivalent vancomycin], diluted in 500mL
normal saline), single antibiotic solution, diluted povidone-
iodine, and normal saline are the most frequently adopted
[91–93]. However, no comparative study on the efficacy of
different irrigation solutions has been carried out yet [56].
Two suction drains are usually positioned, one over
the pectoralis major and under the mastectomy skin flap,
and the other one at the level of the inframammary fold,
coursingmedially [57]. If the implant pocket is subcutaneous,
only one suction drain in the inframammary fold can be
positioned [58]. The skin is commonly closed in two layers
[94] (Figures 1 and 2).
4.4. Postoperative Care. Intravenous prophylactic antibi-
otics are commonly given to patients undergoing direct-to-
implant IBR 60min or less prior to the time of incision [95].
Antibiotic administration should not be continued beyond
the first 24 postoperative hours since there is no recom-
mendation for prolonged postoperative antibiotics unless
drainage is present [56, 96, 97]. In cases where a drain is still
in place after 24 postoperative hours, the role of antibiotics
is controversial, and surgeons should adhere to the hospital
guidelines on antibiotic administration [98–100]. Drains
should be left in place until the output is less than 20mL/24 h,
lowering the thresholds from the classic 30mL/24 h [95].
Soft compression dressings in a nonconstricting surgical
bra are used postoperatively to uniformly distribute very
gentle pressure over the breast. It has been demonstrated
that these measures can reduce both seroma and infection
rates [95]. Postoperative pain is usually not long lasting
and can be easily managed with painkillers. A supportive
brassiere should be worn for the first postoperative month.
Patients should avoid intense physical activity for the first 2-3
weeks.
5. Secondary Procedure
NAC reconstruction can be performed as early as the 2nd
postoperative month by means of local flaps; tattooing is
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Figure 2: Preoperative view (a) and postoperative result (b) after right breast nipple-sparing mastectomy with radial lateral incision and
one-stage implant-based reconstruction. Left breast augmentation with periareolar incision and vertical extension was also performed.
delayed till 6 weeks after NAC reconstruction [101]. Autolo-
gous fat grafting is a safe and effective secondary procedure
after direct-to-implant IBR. Autologous fat grafting can ame-
liorate any residual contour deformities by correcting visible
implant edges, asymmetry with the contralateral breast, and
upper outer defects underneath the anterior axillary fold
[102]. Furthermore, owing to the presence of a stem cell
population, the so-called adipose-derived stem cells, fat grafts
display regenerative potential and therapeutic effects that go
beyond simple filling capability [103–107]. Adipose-derived
stem cells can differentiate into multiple cell lineages and
secrete paracrine factors [108–112]. Thus, angiogenesis and
wound healing are strongly enhanced, leading to higher fat-
graft survival as well as dermal and subcutaneous tissue
regeneration [113–115]. Moreover, autologous fat grafting has
been demonstrated to have positive effects on radiation-
induced soft-tissue damage in reconstructed breasts [116, 117].
Fat grafts can thicken the subcutaneous tissue and improve
the texture of the irradiated skin by enhancing its vascular
supply [118].
6. Complications
Direct-to-implant IBR has the same postoperative compli-
cations as two-stage tissue expander/implant-based breast
reconstructions [74]. However, two-stage breast reconstruc-
tion with submuscular implant pocket has traditionally
been the reconstructive strategy of choice, given its demon-
strated safety, reliability, and effectiveness [119–121]. Direct-
to-implant IBR has recently gained popularity as a conse-
quence of improvements in implant design and the advent of
ADMs/synthetic meshes [17, 122–124].
Reports on the complication rates of direct-to-implant
IBR are controversial, and these rates are supposed to be
higher than those of tissue expander/implant-based recon-
struction [19, 21, 22, 30]. Recently, Basta et al. [74] conducted
the first head-to-head meta-analysis of the outcomes and
complication rates of direct-to-implant IBR versus two-stage
submuscular tissue expander/implant-based breast recon-
struction. The pooled absolute incidence rates of infection
(7.8% versus 7.4%), seroma (6.8% versus 7.1%), hematoma
(4.3% versus 5.2%), and capsule contracture (13.5% ver-
sus 13.8%) did not significantly differ between direct-to-
implant and two-stage tissue expander/implant-based recon-
structions. However, the incidence rates of flap necrosis
(8.6% versus 6.7%), reoperation (17.9% versus 13.8%), and
implant loss (14.4% versus 8.7%) were significantly higher for
direct-to-implant reconstructions. Unfortunately, there was
no mention of whether the reconstructions were implant-
based alone or ADM/mesh-assisted; therefore, no subgroup
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analysis was performed. Similarly, secondary procedure rates
were not reported.
Jagsi et al. [65] retrospectively evaluated a series of
14,894 women undergoing either autologous reconstruction
or direct-to-implant IBR with a mean follow-up of 2 years.
Patients with autologous reconstruction reported higher
wound complication rates (9.5% versus 4.4%) as well as
higher infection rates (20.7% versus 20.5%) than patients
who underwent implant-based reconstructions. Adjuvant
radiation therapy was given to 35% of patients and was
not associated with any infection in any surgical group.
Among patientswho received postoperative radiotherapy, the
rate of implant removal was higher in the alloplastic breast
reconstruction group (21.9% versus 13.1%), while the rate
of fat necrosis was higher in the autologous reconstruction
group (14.7% versus 8.7%).
Sbitany et al. [125] published a systematic review
and meta-analysis of complications associated with ADM-
assisted breast reconstruction compared with traditional
implant-based musculofascial flaps. Skin-flap necrosis was
the most common complication (10.9%), followed by seroma
(6.9%), infection (5.7%), cellulitis (2%), and hematoma
(1.3%).The rate of hematoma was 1.3% (95%CI, 0.6%–2.4%).
Implant removal was necessary in 5.1%of cases. However, the
rate of observed capsule contracture was very low (0.58%).
ADM-assisted reconstruction was associated with a four
times higher rate of seroma formation and nearly 3 times
higher rates of infection and reconstruction failure than non-
ADM-assisted breast reconstruction. Capsule contracture
occurred in 0.58% of ADM-assisted breast reconstructions,
while in the literature, the reported incidence of capsule
contracture after breast reconstructions without the use
of ADM ranges between 3% and 18% [126–129]. Ibrahim
et al. [33] retrospectively analyzed 19,100 alloplastic breast
reconstructions, of which 3301 were ADM-assisted. They
reported no statistically significant difference in the overall
complication rate between breast reconstruction with and
without ADMs. Furthermore, they confirmed that a high
body mass index, diabetes, history of smoking, radiotherapy,
and steroid administration are associated with higher com-
plication rates.
Salibian et al. [47] reviewed subcutaneous implant-based
breast reconstructions with ADMs or meshes. The major
complications (i.e., wide infection, complete NAC necrosis,
complete flap necrosis, explantation, and Baker grade III/IV
capsule contracture) were low in the majority of studies.
Explantation (6%) was the most frequent complication,
followed by seroma (4.9%), partial NAC necrosis (3.9%),
wound healing problems (3.6%), and hematoma (2.4%).
Direct-to-implant IBR and tissue expander/implant-based
breast reconstruction had similar complication rates, even
though statistical analysis could not be performed. However,
interestingly, direct-to-implant IBR had higher explantation
rates (6.0% versus 0%), while tissue expander/implant-based
breast reconstruction had a higher rate of minor infection
(16.0% versus 0%). Furthermore, subgroup analysis was
performed between mesh- and ADM-assisted reconstruc-
tions. The most frequent complication of mesh-assisted
reconstruction was minor infection (6.3%), followed by
partial NAC necrosis (4.2%) and explantation (3.1%). ADM-
assisted reconstructions were associated with higher com-
plication rates: seroma formation, 8.9%; explantation, 6.7%;
and partial NAC necrosis, 5%. The most common patient
complaints after subcutaneous implant-based breast recon-
struction were palpable implants (8.5%), rippling (4.7%), and
visible implants (4.3%). Secondary procedures were needed
in 21.4% of patients, where autologous fat grafting accounted
for 11.9% of patients, and implant exchange was performed in
14.3% of patients [45, 130, 131].
7. Outcome
Direct-to-implant IBR has several potential advantages over
traditional two-staged tissue expander/implant-based recon-
struction such as avoidance of a second operation and no
need for tissue expansion [74, 132, 133]. Indeed, final implant
placement after expansion takes place in the 9th postopera-
tive month on average. This span of time required to obtain
the final result can be perceived as a significant burden to
many patients. Direct-to-implant IBR implies a shorter time
to reach the final reconstruction, which reduces the number
of clinical visits and the sense of mutilation perceived, poten-
tially improving patient quality of life [134, 135]. Nevertheless,
direct-to-implant IBR has considerable wound issues such
as mastectomy flap necrosis, which can vary from minor
epidermolysis to full-thickness necrosis [74, 136]. When
mastectomy flap necrosis occurs during expansion, partial
deflation of the expander can allow surgical debridement
and salvage reconstruction without expander removal. Con-
versely, direct-to-implant IBR more often requires implant
exchange, which potentially compromises the final aesthetic
outcome, lengthens recovery times, decreases the patient’s
quality of life, and delays the administration of adjuvant
therapies, while increasing the economic costs to the patient
and the healthcare system.
These aspects must be clearly discussed with patients in
the preoperative setting, and the surgeon should highlight
not only the possible shorter reconstructive course of direct-
to-implant IBR but also its higher rate of reoperation and/or
initial reconstructive failure. Intraoperative objective assess-
ment tools such as real-time perfusion mapping assisted
by SPY (Novadaq Technologies Inc., Bonita Springs, FL,
USA) can lower the complication rate [89]. However, these
devices are often expensive, time-consuming, and not readily
available at all surgical centers [137].
Submuscular pockets provide additional coverage to
implants [137]. However,muscle dissection can increase post-
operative pain, and the submuscular location of the implant
can result in action deformity and a less natural cosmetic
outcome [138–141]. Furthermore, submuscular pockets can
weaken even modest shoulder joint function, significantly
impacting daily activities [139, 142, 143].
ADM-assisted reconstruction can reduce the operative
time and speed postoperative recovery as a result of lower
postoperative pain and donor-site morbidity [45]. Rapid
return to work and prompt administration of adjuvant
therapy when needed are further advantages. Moreover,
the ADM/mesh-assisted wrapping technique is a muscle
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sparing-technique that can achieve good cosmetic outcome
while preserving the pectoralis major muscle elevation and
occurrence rate of other minor complications [144]. This
approach is particularly suited for elderly patients where fast
recovery and lower morbidity are mandatory for a better
quality of life [58].
ADMs can cost between $2100 and $3400, depending
on the size of the dermal sheet required [145]. However, it
has been found that ADMs are a cost-effective therapeutic
adjunct for breast reconstruction due to their better long-
term aesthetic and clinical benefits [146, 147]. Furthermore,
ADM-assisted reconstructions do not have significantly
higher overall complication rates than non-ADM-assisted
reconstructions but have lower long-term capsule contrac-
ture rates [33, 148, 149]. Given the uncertainties regarding the
indications and contraindications, an algorithmic approach
to aid decision-making with regard to the use of ADMs
has been proposed [150, 151]. Indeed, judicious selection
of candidates, careful evaluation of postmastectomy skin
flaps, and consideration of possible risk factors have demon-
strated the benefits of ADM-assisted breast reconstructions
[57].
8. Conclusions
Direct-to-implant IBR is attractive given the good aesthetic
outcomes, shared advantages with convention two-stage
reconstruction, and patient-satisfaction rate achieved [152–
154]. With the development of ADMs, a paradigm shift from
conventional two-stage breast reconstruction to direct-to-
implant one-stage IBR has been seen [135]. Nevertheless, the
latter surgery has some drawbacks that we believe can be
overcome by careful patient selection and strict adherence
to surgical technique. However, larger comparative studies
and better-defined selection criteria and outcomes reporting
are needed to develop appropriate indications for performing
successful direct-to-implant IBR.
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